.jpg)
1 hour ago
3
Article content
VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
“Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients in need,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “I am pleased to welcome Dr. Sandor to AbCellera’s Board of Directors and look forward to working with him.”
Article content
Article content
Article content
Before its acquisition by Pfizer Inc., Dr. Sandor served as Chief Medical Officer at Array BioPharma Inc. where he successfully secured approval of Braftovi® (encorafenib) and Mektovi® (binimetinib). Prior to joining Array, Dr. Sandor served as Senior Vice President for Global Clinical Development at Incyte Corporation, where he played a critical role in the approval of Jakafi® (ruxolitinib). Dr. Sandor was also Vice President and Chief Medical Officer for Oncology at Biogen Inc. and held positions of increasing responsibility in oncology product development at AstraZeneca Pharmaceuticals LP, contributing to the registration of Arimidex® (anastrozole) and the development of Faslodex® (fulvestrant).
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“I am excited to join the AbCellera board at this important moment in the company’s evolution. AbCellera has established an exceptional capability in antibody discovery, and I look forward to working with Carl and the team as the company advances its pipeline and translates that capability into meaningful clinical outcomes for patients,” said Dr. Sandor.
Article content
Dr. Sandor currently serves on the board of directors at ADC Therapeutics SA, Kymera Therapeutics Inc., and Prelude Therapeutics Incorporated. He also served on the board of Merus N.V. prior to its acquisition by Genmab A/S in 2025.
Article content
Dr. Sandor received his M.D.C.M. from McGill University in Montreal, Canada, and completed a Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland.
Article content
About AbCellera Biologics Inc.
Article content
Article content
(Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit
Article content
Article content
.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
Inquiries
Article content
Media: Tiffany Chiu; [email protected], +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005
Investor Relations: Peter Ahn; [email protected], +1(778)729-9116
Article content
English (US)